Physician profile
Sanjeev Jain
NPI 1710973839
$25,236.72
in general payments reported to CMS, 2019-2025
49 companies · $4,210 in 2025
The $4,210 reported for 2025 was more than what 82% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,165 · 2020: $2,559 · 2021: $3,134 · 2022: $3,609 · 2023: $4,200 · 2024: $4,359 · 2025: $4,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $212 · Consulting Fee: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,377.10 |
| Education | $212.37 |
| Consulting Fee | $180.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,578.41 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $4,478.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,620.72 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $1,474.39 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $1,365.23 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pfizer INC. | $1,120.58 | 2019-2025 | |
| Octapharma USA, INC. | $1,028.05 | 2019-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $1,025.51 | 2019-2025 | |
| Genzyme Corporation | $1,012.63 | 2019-2025 | |
| Amgen INC. | $950.38 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $863.54 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $767.48 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $545.80 | 2021-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.08 | 2019-2023 | |
| Biocryst US Sales Co., LLC | $404.30 | 2021-2025 | Orladeyo |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $366.89 | 2019-2024 | Auvi-Q |
| Abbvie INC. | $318.44 | 2022-2023 | |
| Pharming Healthcare, INC. | $301.02 | 2019-2025 | Ruconest |
| Optinose US, INC. | $279.93 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $263.58 | 2019-2022 | |
| Harmony Biosciences LLC | $199.86 | 2024-2025 | |
| Adma Biomanufacturing LLC | $180.13 | 2023-2025 | |
| Tersera Therapeutics LLC | $167.03 | 2022-2025 | Quzyttir |
| Bio Products Laboratory USA, INC. | $159.93 | 2021-2023 | Coagadex, Gammaplex |
| Shire North American Group INC | $146.97 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $125.99 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $99.19 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $94.39 | 2021-2023 | Belsomra |
| Covis Pharma Gmbh | $77.61 | 2020-2022 | |
| Alk-Abello, INC | $77.37 | 2021-2024 | Odactra, Grastek, Ragwitek |
| Horizon Therapeutics Plc | $59.65 | 2019-2023 | Actimmune |
| Greer Laboratories, INC. | $57.60 | 2019-2025 | Oralair |
| Mylan Specialty L.P. | $52.70 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $46.40 | 2024-2025 | Ebglyss |
| Kowa Pharmaceuticals America, INC. | $45.05 | 2025 | Zoryve |
| Phadia US INC. | $44.54 | 2024 | Immunocap |
| Biocryst Pharmaceuticals, INC. | $42.12 | 2020 | |
| Galderma Laboratories, L.P. | $37.34 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $33.55 | 2025 | Sajazir |
| Dermavant Sciences, INC. | $27.30 | 2024 | Vtama |
| Viatris Specialty LLC | $26.25 | 2025 | Yupelri |
| Incyte Corporation | $26.08 | 2024 | Opzelura |
| Organon LLC | $25.79 | 2025 | Vtama |
| Circassia INC. | $25.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.33 | 2024 | Keveyis |
| Verona Pharma, INC. | $21.91 | 2025 | Ohtuvayre |
| Genentech, INC. | $20.65 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.